Evidence map›Paper›PMID 42182159›Full record

ArticlebioRxiv : the preprint server for biology2026

Potent reaction hijacking inhibitors of

Xi Ye, Lisl Y Esherick, Nutpakal Ketprasit, Sunil K Narwal, Luiz C Godoy, Nonlawat Boonyalai, Con Dogovski, Craig J Morton, Tayla Rabie, Mufuliat Toyin Famodimu and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Xi YeDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Lisl Y EsherickDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nutpakal KetprasitDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Sunil K NarwalDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Luiz C GodoyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Nonlawat BoonyalaiBiological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dundee DD1 4HN, United Kingdom.
Con DogovskiDrug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
Craig J MortonBiotherapeutics Program CSIRO, Clayton South, Australia.
Tayla RabieDepartment of Biochemistry, Genetics and Microbiology, University of Pretoria, Private Bag X20, Hatfield 0028, South Africa.
Mufuliat Toyin FamodimuLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Chia-Wei TaiDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Lena H M LeDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Michael G LeemingMelbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
Mariana Laureano De SouzaDepartment of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Elodie ChenuMedicines for Malaria Venture, 20, Route de Pré-Bois, 1215, Geneva 15, Switzerland.
Darren J CreekDrug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.ORCID 0000-0001-7497-7082
Michael J DelvesLondon School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Lyn-Marie BirkholtzDepartment of Biochemistry, Genetics and Microbiology, University of Pretoria, Private Bag X20, Hatfield 0028, South Africa.
James DuffyMedicines for Malaria Venture, 20, Route de Pré-Bois, 1215, Geneva 15, Switzerland.
Karen LobbLgenia, Inc., 412 S Maple St, Fortville, IN, USA.
Greg DurstLgenia, Inc., 412 S Maple St, Fortville, IN, USA.
Marcus C S LeeBiological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dundee DD1 4HN, United Kingdom.ORCID 0000-0002-4973-0915
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Miles G SiegelLgenia, Inc., 412 S Maple St, Fortville, IN, USA.
Leann TilleyDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0001-9910-0199
Stanley C XieDepartment of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.

Funding

Defining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeuticsR01AI185559 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2024 to 2026
$1.9M
Bill & Melinda Gates Foundation INV-026505NIAID NIH HHS R01 AI185559
6 · The paper itself

Abstract

Malaria remains one of the major threats to human health. Breakthrough drugs with high potency and low resistance risk are needed to combat the ever-increasing resistance to currently deployed antimalarials. Here, we explore a series of 4-amino-quinazoline-based sulfonamides, with drug-like physicochemical parameters and a synthetically accessible scaffold. Exemplars exhibit nanomolar potency against blood stage

Identifiers

PMID42182159
PMCPMC13193014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.